Simultaneous vs sequential treatment with ingenol mebutate of two areas with actinic keratoses (AKs) on face/scalp and trunk/extremities

被引：0

|

作者：

Pellacani, Giovanni ^{[1
]}

Peris, Ketty ^{[2
]}

Guillen, Carlos ^{[3
]}

Clonier, Fabrice ^{[4
]}

Larsson, Thomas ^{[5
]}

Puig, Susana ^{[6
]}

机构：

[1] Univ Modena & Reggio Emilia, Modena, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Inst Valenciano Oncol, Serv Dermatol, Valencia, Spain

[4] Labs LEO, Voisins Le Bretonneux, France

[5] LEO Pharma AS, Ballerup, Denmark

[6] Univ Barcelona, St Pere de Ribes, Barcelona, Spain

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2015年 / 72卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

1269

引用

收藏

页码：AB192 / AB192

页数：1

相关论文

共 33 条

[31] Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles
Hanke, C. William
Beer, Kenneth R.
Stockfleth, Eggert
Wu, Jason
Rosen, Theodore
Levy, Sharon
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (04) : 573 - 581
[32] Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques
Ruini, Cristel
Hartmann, Daniela
Bastian, Mike
Ruzicka, Thomas
French, Lars E.
Berking, Carola
von Braunmuehl, Tanja
JOURNAL OF BIOPHOTONICS, 2019, 12 (07)
[33] Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100cm2 in patients with actinic keratoses
Schmieder, George
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB106 - AB106

← 1 2 3 4 →